Novo Nordisk A/S
NVO
|
News
|
$126.16
-1.93%
-0.23%
3.1M
|
Health Technology
(0.0% 1d) (-0.3% 1m) (-23.7% 1y) (0.0% 2d) (2.7% 3d) (4.8% 7d) (-100.0% volume)
Earnings Calendar:
Market Cap: $ 433,375,748,480
http://www.novonordisk.com
Sec Filling | Patents | 43258 employees
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
obesity diabetes haemophilia insulin diabetic hormone growth hormone
add to watch list Paper trade email alert is off
Press-releases
Novo Nordisk A/S - Articles of Association, April 2024
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -1.31%
H: 0.0%
C: 0.0%
Novo Nordisk A/S – Reduction of the share capital
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -1.31%
H: 0.0%
C: 0.0%
Novo Nordisk A/S - share repurchase programme
Published: 2024-04-22 (Crawled : 13:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.1%
H: 2.99%
C: 2.18%
repurchase
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
Published: 2024-04-22 (Crawled : 18:00) - biospace.com/
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.1%
H: 2.99%
C: 2.18%
snipr001 cancer trials funding
Peptide Therapeutics Market Projected to Reach $57.97 billion by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 15:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: 0.24%
H: 0.42%
C: 0.42%
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: -0.84%
H: 0.86%
C: -0.62%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -3.05%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.18%
H: 0.84%
C: 0.6%
report reach therapeutics market
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 1.22%
H: 0.21%
C: -0.34%
vent-02 trial therapeutics results
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: 2024-04-15 (Crawled : 18:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 1.04%
H: 0.19%
C: -1.52%
Novo Nordisk A/S - share repurchase programme
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 1.04%
H: 0.19%
C: -1.52%
repurchase
Novo Nordisk A/S - share repurchase programme
Published: 2024-04-08 (Crawled : 13:30) - globenewswire.com
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 1.62%
H: 0.5%
C: 0.36%
repurchase
Ventus Therapeutics to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
Published: 2024-04-08 (Crawled : 12:30) - biospace.com/
NVO | News | $126.16 -1.93% -0.23% 3.1M
|
Health Technology
|
| O: 1.62%
H: 0.5%
C: 0.36%
conference therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
ILAG | $0.51 6.03% 29.06% 430K
|
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
TGEN P 16000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
WABC | $47.86 0.21% 0.21% 140K
|
Finance
|
19:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
17:00
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
TPL P 3 | $589.01 0.2% -0.04% 53K
|
Miscellaneous
|
15:01
ISBA P 966 | $18.0001 1.63% 3.1K
|
Finance and Insurance
|
15:01
MEGI | $12.02 0.33% -0.08% 150K
|
|
00:30
CTRN P 29000 | $22.11 -0.54% -0.54% 65K
|
Retail Trade
|
22:00
CONN | $3.78 2.16% 2.12% 36K
|
Retail Trade
|
21:30
CMTV P 700 | $16.59 17.43% 1K
|
Finance and Insurance
|
18:30
FNB | $13.67 0.29% 0.0% 2.2M
|
Finance
|
17:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10